Cellectar Biosciences
CLRB
14 hedge funds and large institutions have $4.34M invested in Cellectar Biosciences in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
631% more capital invested
Capital invested by funds: $593K → $4.34M (+$3.74M)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
27% more funds holding
Funds holding: 11 → 14 (+3)
0.05% more ownership
Funds ownership: 0.02% → 0.07% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$2.09M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.55M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$241K |
| 4 |
Renaissance Technologies
New York
|
+$151K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$30.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$42K |
| 2 |
Morgan Stanley
New York
|
-$40.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Boxer Capital
San Diego,
California
| $2.01M | +$2.09M | +3,067 | New |
|
|
TCM
2
Tang Capital Management
San Diego,
California
| $1.48M | +$1.55M | +2,267 | New |
|
|
3
Renaissance Technologies
New York
| $268K | +$151K | +221 | +117% |
|
|
CH
4
CVI Holdings
Wilmington,
Delaware
| $231K | +$241K | +353 | New |
|
|
SFM
5
Sphera Funds Management
Tel Aviv,
Israel
| $191K | – | – | – |
|
|
6
Morgan Stanley
New York
| $77K | -$40.9K | -60 | -34% |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $37K | – | – | – |
|
8
Dimensional Fund Advisors
Austin,
Texas
| $22K | – | – | – |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $9K | +$4.77K | +7 | +117% |
|
10
US Bancorp
Minneapolis,
Minnesota
| $6K | – | – | – |
|
|
AIC
11
AWM Investment Company
New York
| $5K | – | – | – |
|
|
SIM
12
Sonora Investment Management
Tucson,
Arizona
| $1K | – | – | – |
|
|
KFS
13
Kelly Financial Services
Braintree,
Massachusetts
| $59 | – | – | – |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$42K | -59 | Closed |
|
|
PAG
15
Private Advisor Group
Morristown,
New Jersey
| – | +$30.7K | +45 | New |
|
CLRB Hedge Fund Activity: Q2 2019 in Review
14 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2019, worth a combined $4.34M — up 631% from $593K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLRB positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $2.09M. The largest seller was Citadel Advisors, exiting entirely with an estimated $42K sold.
- 14 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2019, up from 11 in Q1 2019.
- Funds reported $4.34M of Cellectar Biosciences stock for Q2 2019, up 631% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q2 2019 and 1 closed out, a net change of +3 holders.
- The largest Cellectar Biosciences buyer in Q2 2019 was Boxer Capital, an estimated $2.09M added.
- The largest Cellectar Biosciences seller in Q2 2019 was Citadel Advisors, an estimated $42K sold.
Based on aggregated 13F filings for Q2 2019.